ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
bullish•Fuji Soft Inc
•15 Dec 2024 06:30

(Mostly) Asia-Pac M&A: Insignia, Fosun Tourism, GJS/Haitong, Fuji Soft, Dexus Property

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
387 Views
Share
bullish•VCredit Holdings Ltd
•12 Dec 2024 13:27

VCredit (2003 HK): Ma Makes His Move?

VCredit is down 90% from its 2018 listing.  VCredit is currently suspended pursuant to the Takeovers Code. Now might be the time for the Chairman...

Logo
446 Views
Share
•10 Dec 2024 08:55

Shanghai Fosun Pharmaceutical (2196.HK) - Performance Pain Points and Henlius’ Privatization Outlook

​Fosun Pharma's investment-driven business model relies heavily on subsidiaries.Privatization of Henlius may face uncertainties if not prioritized...

Logo
652 Views
Share
bullish•HKBN Ltd
•09 Dec 2024 01:26

Merger Arb Mondays (09 Dec) - HKBN, ESR, Lifestyle China, GA Pack, Latin Res, De Grey, SG Fleet

This week, the highest gross spreads are Lifestyle China (21.7%), Arcadium Lithium (11.4%), Henlius (11.1%), ESR (9.2%), Get Nice (8.7%), Canvest...

Logo
771 Views
Share
bullish•ESR Group
•08 Dec 2024 06:30

(Mostly) Asia-Pac M&A: De Grey Mining, HPI, SG Fleet, Malaysia Airports, MPHB, Suntec REIT

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
718 Views
Share
x